Employees of the FGBI ARRIAH studied the effectiveness of domestic vaccines against the epizootic influenza A/H5N1 virus isolated from gulls in the Russian Federation

As part of the study , two samples of vaccine preparations were studied:

 - based on the antigen of the low pathogenic H5N1 virus produced by FGBI "ARRIAH" with the commercial name "AviFluVac";

- based on the antigen of the highly pathogenic H5N1 virus from another domestic manufacturer.

Preparations containing various concentrations of antigens have been investigated to establish a protective dose.

Both drugs, when used in a single vaccination dose, showed a 100-fold protective effect: all vaccinated birds, after control infection with a virulent influenza virus isolate isolated from gulls in May 2023, were alive and clinically healthy against the background of 100 bird deaths in the control group.

However, with the introduction of vaccines in dilutions of 1:25-1:100, it was found that one inoculation dose of the AviFluVac vaccine contains 96 PD50, while the above-mentioned figure for the preparation of another domestic manufacturer was only 38 PD50.

The World Organization for Animal HEALTH (OIE) recommends the use of vaccines containing 50 PD50 in one vaccination dose for the prevention of highly pathogenic avian influenza.

FGBI ARRIAH, being the OIE Reference Laboratory for avian influenza, develops and manufactures specific prevention and diagnostic tools (test systems and vaccines) in accordance with international standards.